Literature DB >> 7533773

T-cells recognize multiple epitopes in the human thyrotropin receptor extracellular domain.

M Soliman1, E Kaplan, T Yanagawa, Y Hidaka, M E Fisfalen, L J DeGroot.   

Abstract

In Graves' disease (GD), the TSH receptor (TSHR) is believed to be the major target of an autoimmune response. T-Lymphocytes regulate the immune system. To assess the interaction of T-cells with TSHR in the pathogenesis of GD, we tested the T-cell response of peripheral blood mononuclear cells and T-cell lines to the recombinant human TSHR extracellular domain (rhTSHR-ECD) and 31 synthetic peptides corresponding to the entire TSHR-ECD in 20 patients with GD, 8 patients with Hashimoto's thyroiditis, 7 with colloid nodular goiter (CNG), and 20 normal controls. Comparing patients from different groups with normal subjects, there was a significant response to rhTSHR-ECD and thyroglobulin in GD patients (P < 0.001) and HT patients (P < 0.05), but not in CNG patients (P > 0.1). All 20 patients with GD responded to at least one peptide. The reactivity in GD patients was heterogeneous and spanned the entire TSHR-ECD. However, the reactivity was significantly different from that in controls for peptide regions 44-88, 119-176, 227-263, and 343-376, and the stimulation index (SI) values were significantly different for peptides 272-291 and 301-320. Significant differences were confined to peptides 158-176 and 343-362 and the region 227-263 for comparison of the number of positive responses in patients and controls to individual peptides. Forty-six percent of human leukocyte antigen-DQA1 0501 allele-positive Graves' patients responded to peptides 158-176 and 248-263 (SI = 3 or more) compared to 14% of allele-negative patients. In HT and CNG patients, the response was mainly to peptides in the carboxy-terminal half of the TSHR-ECD. Concordance of the reactivity in T-cell lines and peripheral blood mononuclear cells was observed in 36% of direct comparisons in GD. Eighty-five percent and 90% of GD patients were positive for microsomal antibody and TSHR antibody, respectively, and 59% of microsomal antibody-positive and 67% of TSHR antibody-positive patients responded to rhTSHR-ECD (SI = 2 or more). However, there was no significant correlation between antibody-positive patients and reactivity to specific peptides. Using multiple criteria to define immunodominance, peptides 158-176, 237-252, 248-263, and 343-362 seem to be important epitopes and may be critical for T-cell triggering in GD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533773     DOI: 10.1210/jcem.80.3.7533773

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Concurrent Graves' disease and intracranial arterial stenosis/occlusion: special considerations regarding the state of thyroid function, etiology, and treatment.

Authors:  Shigeo Ohba; Toru Nakagawa; Hideki Murakami
Journal:  Neurosurg Rev       Date:  2011-03-19       Impact factor: 3.042

2.  Cepharanthine blocks TSH receptor peptide presentation by HLA-DR3: Therapeutic implications to Graves' disease.

Authors:  Cheuk Wun Li; Roman Osman; Francesca Menconi; Erlinda Concepcion; Yaron Tomer
Journal:  J Autoimmun       Date:  2020-01-21       Impact factor: 7.094

3.  The role of glutamic or aspartic acid in position four of the epitope binding motif and thyrotropin receptor-extracellular domain epitope selection in Graves' disease.

Authors:  Hidefumi Inaba; William Martin; Matt Ardito; Anne Searls De Groot; Leslie J De Groot
Journal:  J Clin Endocrinol Metab       Date:  2010-04-14       Impact factor: 5.958

4.  Epitope recognition in HLA-DR3 transgenic mice immunized to TSH-R protein or peptides.

Authors:  Hidefumi Inaba; Leonard Moise; William Martin; Anne S De Groot; Joe Desrosiers; Ryan Tassone; George Buchman; Takashi Akamizu; Leslie J De Groot
Journal:  Endocrinology       Date:  2013-04-16       Impact factor: 4.736

Review 5.  Genetic background and environment contribute synergistically to the onset of autoimmune diseases.

Authors:  P Luppi; M R Rossiello; S Faas; M Trucco
Journal:  J Mol Med (Berl)       Date:  1995-08       Impact factor: 4.599

6.  Evaluation of T cell stimulation by thyrotropin-receptor epitopes in Graves' disease.

Authors:  L J De Groot; Y Ha Shin; D Pan; G Gopalakrishnan; J V Hennessey
Journal:  J Endocrinol Invest       Date:  2009-01       Impact factor: 4.256

Review 7.  Thyrotropin Receptor Epitope and Human Leukocyte Antigen in Graves' Disease.

Authors:  Hidefumi Inaba; Leslie J De Groot; Takashi Akamizu
Journal:  Front Endocrinol (Lausanne)       Date:  2016-08-23       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.